title: Soluble CD14 promotes LPS activation of CD14-deficient PNH monocytes and endothelial cells.
abstract: Bacterial lipopolysaccharide (LPS) initiates the cascade of inflammatory events that, in infected patients, often result in a lethal systemic inflammatory response known as the sepsis syndrome. We studied LPS-stimulated expression of tissue factor (TF) in human peripheral blood mononuclear cells (PBMCs) and cultured endothelial cells or tumor necrosis factor-alpha (TNF-alpha) in PBMCs. CD14, a PBMC membrane protein, is involved in LPS signaling and is also present as a soluble molecule in serum. CD14 is absent from endothelial cells and, in varying degrees, from monocytes of patients with paroxysmal nocturnal hemoglobinuria (PNH). LPS stimulation of TF in normal monocytes was enhanced > 30-fold by serum at low concentrations of LPS (< or = 10 ng/ml). The serum dependence of endothelial cells was even more pronounced; a full response to LPS was not observed in endothelium under serum-free conditions, even with LPS concentrations as high as 100 ng/ml. To better define the role of CD14, CD14-deficient PBMCs from two patients with PNH were compared with normal PBMCs. Although less than 3% of PNH monocytes expressed CD14, LPS-induced synthesis of TF and TNF-alpha by PBMCs from PNH patients was inhibited by anti-CD14 antibodies. Because patient serum samples were found to contain soluble CD14, we sought to determine whether PNH monocytes might respond to LPS through an activation pathway dependent on soluble CD14. Recombinant soluble CD14 substituted for serum to enable LPS stimulation of endothelium, PNH PBMCs, and surprisingly, CD14-replete normal PBMCs. In addition, a truncated sCD14 containing the N-terminal 152 amino acids similarly enabled LPS stimulation of normal PBMCs. These data underscore the importance of soluble CD14 and suggest that CD14 present in serum enables LPS responses in PNH monocytes and endothelial cells and may even influence the effects of LPS in normal human phagocytes.
authors.affiliation: Department of Internal Medicine, Maxwell Finland Laboratory for Infectious Diseases, Boston City Hospital, Massachusetts, USA.
authors.forename: D T
authors.initials: DT
authors.lastname: Golenbock
authors.forename: R R
authors.initials: RR
authors.lastname: Bach
authors.forename: H
authors.initials: H
authors.lastname: Lichenstein
authors.forename: T S
authors.initials: TS
authors.lastname: Juan
authors.forename: A
authors.initials: A
authors.lastname: Tadavarthy
authors.forename: C F
authors.initials: CF
authors.lastname: Moldow
mesh_terms: D015703:Antigens, CD / Q000032:analysis / Q000502:physiology*; D015214:Antigens, Differentiation, Myelomonocytic / Q000032:analysis / Q000502:physiology*; D004730:Endothelium, Vascular / Q000378:metabolism*; D006457:Hemoglobinuria, Paroxysmal / Q000097:blood / Q000276:immunology / Q000378:metabolism*; D006801:Humans; D018950:Lipopolysaccharide Receptors; D008070:Lipopolysaccharides / Q000494:pharmacology*; D009000:Monocytes / Q000378:metabolism*; D012995:Solubility; D013925:Thromboplastin / Q000096:biosynthesis
chemical_list: D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D018950:Lipopolysaccharide Receptors; D008070:Lipopolysaccharides; D013925:Thromboplastin